Regulatory Challenges for Chinese Biotech Expanding Trials to Europe – Part 3
As Chinese biotech companies expand their clinical development programs into Europe, a thorough understanding of EU regulatory expectations becomes critical. At the center of the EU Clinical Trial Application (CTA) process is the Investigational Medicinal Product Dossier (IMPD), the key document regulators use to evaluate the quality, safety, and scientific rationale for administering an investigational product to humans.
This third article in our Regulatory Challenges for Chinese Biotech Expanding Trials to Europe series outlines the essential elements of a compliant IMPD and underscores the importance of seamless alignment with the broader CTA package.
The Role of the IMPD in EU Clinical Trial Authorization
The IMPD provides a structured and comprehensive overview of the investigational product, demonstrating that it is manufactured in accordance with appropriate standards, supported by adequate non-clinical and clinical evidence, and suitable for use in the proposed trial.
For Chinese sponsors entering the European regulatory environment, the IMPD often represents the first major test of compliance with EU-specific expectations, particularly with respect to CMC transparency, GMP requirements, and structured scientific justification.
Core Components of a Compliant IMPD
- Quality (CMC) Information
Regulators expect clear, detailed documentation of manufacturing processes, control strategies, analytical methods, stability data, and EU GMP (Good Manufacturing Practices) compliance. For complex biologics or advanced therapies, process characterization and robustness of controls are subject to heightened scrutiny due to their complex mechanism of action.
- Non-Clinical Evidence
Pharmacology and GLP-compliant toxicology data must adequately support the proposed human dose and regimen. Authorities assess the relevance of the animals or models used, selected endpoints, and exposure margins in relation to the planned clinical trial design.
- Clinical Experience
All available human clinical data must be summarized clearly, or the absence of such data must be scientifically justified. This can include published literature also. Dose selection rationale, emerging safety findings, and risk mitigation strategies should be presented transparently.
- Integrated Risk–Benefit Assessment
A concise, balanced assessment integrating quality, non-clinical, and clinical data, with a clear link to the safety monitoring measures described in the clinical protocol.
Ensuring Alignment Between the IMPD and CTA Package
Even a well-prepared IMPD may raise regulatory concerns if inconsistencies exist within the broader CTA submission. EU authorities review all CTA documents collectively, including the protocol, Investigator’s Brochure, patient-facing materials, and handling instructions of the investigational medicinal product (IMP).
Key areas requiring careful alignment include:
- Dose and administration: Justification presented in the IMPD must align with the proposed clinical protocol.
- Safety measures: Identified risks must be reflected consistently in monitoring plans and patient information.
- IMP storage and handling: Completed stability data must support shipping and logistics instructions.
- Scientific rationale: A coherent narrative should underpin all documents.
For many Chinese biotech companies, achieving this level of consistency requires adapting documentation originally developed for non-EU regulatory frameworks.
Best Practices for Chinese Biotech Sponsors
- Perform an EU-focused data gap analysis early in development
- Ensure your supporting quality documents meet EU compliance e.g. Ph. Eur. Monographs and ensure your facility is in compliance with EU or EMA requirements
- Ensure close alignment across CMC, non-clinical, and clinical teams
- Understand country-specific nuances under the EU Clinical Trials Regulation (CTR)
- Use clear, regulator-oriented language throughout submission documents
- Plan early for EU supply chain requirements, including QP release for imported IMPs
Conclusion
A robust IMPD, fully aligned with the CTA package, is essential for successful entry into Europe’s clinical trial landscape. By prioritizing data completeness, cross-document consistency, and EU-specific quality expectations, Chinese biotech companies can reduce regulatory risk, minimize delays, and accelerate trial initiation.
This article continues our exploration of regulatory challenges facing Chinese biotech companies expanding into Europe. The next installment will focus on additional operational and compliance considerations to support successful global clinical development.
Previous blog: Bridging Regulatory Systems: From China’s IND to Europe’s CTA – Caidya®